Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven metastatic breast, lung, or prostate cancer
• Measurable disease
• No untreated CNS metastases
• No symptomatic CNS metastases requiring escalating doses of corticosteroids
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age
• 65 and over
• Sex
• Not specified
• Menopausal status
• Not specified
• Performance status
• Karnofsky 70-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Hemoglobin at least 8.0 g/dL
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin normal
• SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN) with alkaline phosphatase no greater than ULN OR
• Alkaline phosphatase no greater than 4 times ULN with SGOT and SGPT no greater than ULN
• Renal
• Not specified
• Cardiovascular
• No history of cardiac arrhythmia
• No congestive heart failure
• No myocardial infarction within the past 6 months
• Other
• No prior severe hypersensitivity reaction to docetaxel or other drugs containing polysorbate 80
• No allergy to macrolide antibiotics
• No grade 2 or greater peripheral neuropathy
• No concurrent serious or uncontrolled infection
• Able to read, write, and converse in English
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Recovered from prior chemotherapy
• Endocrine therapy
• See Disease Characteristics
• Radiotherapy
• Recovered from prior radiotherapy
• Surgery
• Not specified
• Other
• No concurrent CYP3A4-inducing or inhibiting medications or herbal remedies
• No concurrent grapefruit juice
• No concurrent ethanol